Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Pre-Exposure Prophylaxis Study of Lenacapavir in Cisgender Men, Transgender Women, Transgender Men, and Gender Nonbinary People at Risk for HIV Infection (PURPOSE 2)

11 de setembro de 2026 atualizado por: Gilead Sciences

Um estudo de fase 3, duplo-cego, multicêntrico e randomizado para avaliar a eficácia e a segurança do Lenacapavir subcutâneo duas vezes ao ano de longa duração para profilaxia pré-exposição ao HIV em homens cisgêneros, mulheres transgêneros, homens transgêneros e pessoas não binárias de gênero ≥ 16 anos de idade Idade que fazem sexo com parceiros do sexo masculino e correm o risco de infecção pelo HIV

The goal of this study is to evaluate the efficacy of the study drugs, lenacapavir (LEN) in preventing HIV infection, in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV-1 infection.

The primary objective of this study is to evaluate the efficacy of LEN for HIV-1 pre-exposure prophylaxis (PrEP) in participants ≥ 16 years of age who have condomless receptive anal sex with partners assigned male at birth at risk of HIV-1 infection.

Visão geral do estudo

Status

Ativo, não recrutando

Condições

Intervenção / Tratamento

Tipo de estudo

Intervencional

Inscrição (Real)

3292

Estágio

  • Fase 3

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

      • Buenos Aires, Argentina, 1072
        • Hospital General de Agudos JM Ramos Mejia
      • Buenos Aires, Argentina, B7600
        • Instituto de Investigaciones Clinicas Mar del Plata
      • Buenos Aires, Argentina, 1202
        • Fundacion Huesped
      • Belo Horizonte - MG, Brasil, 30130-100
        • Unidade de Pesquisa Clinica em Vacinas (UPqVac) da Faculdade de Medicina da Universidade
      • Canela-Salvador, Brasil, 40110-060
        • Fundação Bahiana de Infectologia
      • Manauas, Brasil, 69040-000
        • Fundação de Medicina Tropical Doutor Heitor Vieira Dourado / Fundação Medicina Tropical do Amazonas - FMT/IMT/AM
      • Nova Iguaçu, Brasil, 26030-380
        • Hospital General de Nova Iguaçu - HGNI
      • Porto Alegre, Brasil, RS 91350 200
        • Grupo Hospitalar Conceição/ Hospital Nossa Senhora da Conceição S.A.
      • Rio de Janeiro, Brasil, 21040-360
        • Instituto Nacional de Infectologia Evandro Chagas / Fundação Oswaldo Cruz - INI FIOCRUZ
      • São Paulo, Brasil, 01246-903
        • Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
      • São Paulo, Brasil, 04121-000
        • Centro de Referência e Treinamento DST/AIDS
      • São Paulo, Brasil, 06519-332
        • Center for Management and Research. SPDM-Paulista Association for the Development of Medicine-Hospital São Paulo/Federal
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35233
        • UAB Sexual Health Research Clinic
    • California
      • Loma Linda, California, Estados Unidos, 92354
        • Loma Linda University Clinical Trial Center Clinic
      • Los Angeles, California, Estados Unidos, 90069
        • Mills Clinical Research
      • Los Angeles, California, Estados Unidos, 90036
        • Ruane Clinical Research Group Inc.
      • Los Angeles, California, Estados Unidos, 90038
        • UCLA CBAM Vine Street Clinic
      • Los Angeles, California, Estados Unidos, 90059
        • Charles R. Drew University of Medicine and Science (CDU) - Clinical Translational Research Center (CTRC)
      • Los Angeles, California, Estados Unidos, 90502
        • The Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
      • Palm Springs, California, Estados Unidos, 92262
        • BIOS Clinical Research
      • San Diego, California, Estados Unidos, 92103
        • UCSD Anti Viral Research Center
      • San Francisco, California, Estados Unidos, 94102
        • Optimus Medical Group
      • San Francisco, California, Estados Unidos, 94102
        • Bridge HIV at the San Francisco Department of Public Health
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • University of Colorado Clinical and Translational Research Centers (CTRC)
    • Connecticut
      • New Haven, Connecticut, Estados Unidos, 06510
        • Yale University, School of Medicine
    • District of Columbia
      • Washington D.C., District of Columbia, Estados Unidos, 20009
        • Whitman-Walker Institute Inc.
      • Washington D.C., District of Columbia, Estados Unidos, 20017
        • Washington Health Institute
    • Florida
      • Fort Lauderdale, Florida, Estados Unidos, 33308
        • Therafirst Medical Center
      • Fort Lauderdale, Florida, Estados Unidos, 33316
        • Gary Richmond, MD, PA
      • Ft. Pierce, Florida, Estados Unidos, 34982
        • Midway Immunology & Research Center, LLC
      • Jacksonville, Florida, Estados Unidos, 32207
        • CAN Community Health Clinic
      • Miami, Florida, Estados Unidos, 33136
        • University of Miami Miller School of Medicine Division of Infectious Disease Research - Converge Miami
      • Miami Gardens, Florida, Estados Unidos, 33055
        • CAN Community Health
      • Orlando, Florida, Estados Unidos, 32803
        • Orlando Immunology Center
      • Sarasota, Florida, Estados Unidos, 34237
        • CAN Community Health
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30303
        • Emory University
      • Atlanta, Georgia, Estados Unidos, 30308
        • Emory University Hospital Midtown Infectious Disease Clinic
      • Atlanta, Georgia, Estados Unidos, 30030
        • The Hope Clinic at Emory University
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60613
        • Howard Brown Health Center
      • Chicago, Illinois, Estados Unidos, 60612
        • RMR Core Center
      • Chicago, Illinois, Estados Unidos, 60612
        • University of Illinois at Chicago, Department of Medicine, Division of Infectious Diseases, Project WISH
    • Indiana
      • Indianapolis, Indiana, Estados Unidos, 46202
        • Indiana University Infectious Diseases Research
    • Kentucky
      • Lexington, Kentucky, Estados Unidos, 40503
        • Baptist Health Lexington
      • Louisville, Kentucky, Estados Unidos, 40241
        • Norton Infectious Disease Specialists
    • Louisiana
      • New Orleans, Louisiana, Estados Unidos, 70119
        • LSU-CrescentCare Sexual Health Center- New Orleans Community Health Center
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21287
        • Johns Hopkins University School of Medicine
    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02215
        • The Fenway Institute
    • Michigan
      • Berkley, Michigan, Estados Unidos, 48072
        • Be Well Medical Center
      • Detroit, Michigan, Estados Unidos, 48202
        • Henry Ford Hospital
    • Mississippi
      • Jackson, Mississippi, Estados Unidos, 39202
        • Open Arms Healthcare Center
    • Missouri
      • Kansas City, Missouri, Estados Unidos, 64111
        • KC CARE Health Center
    • New Jersey
      • Newark, New Jersey, Estados Unidos, 07102
        • St. Michael's Medical Center
      • Somers Point, New Jersey, Estados Unidos, 08244
        • South Jersey Infectious Disease
    • New York
      • New York, New York, Estados Unidos, 10029
        • Icahn School of Medicine at Mount Sinai- Mount Sinai Downtown
    • North Carolina
      • Chapel Hill, North Carolina, Estados Unidos, 27514
        • NC TraCS Institute - CTRC; University of North Carolina at Chapel Hill
      • Greensboro, North Carolina, Estados Unidos, 27401
        • Cone Health/Regional Center for Infectious Disease Research Center
      • Winston-Salem, North Carolina, Estados Unidos, 27103
        • Wake Forest University Health Sciences
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45267
        • University of Cincinnati
      • Columbus, Ohio, Estados Unidos, 43210
        • The Ohio State University Wexner Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Penn Prevention Unit
      • Philadelphia, Pennsylvania, Estados Unidos, 19107
        • Philadelphia FIGHT Community Health Centers, Jonathan Lax Treatment Center
    • South Carolina
      • Charleston, South Carolina, Estados Unidos, 29425
        • Medical University of South Carolina, Infectious Disease Clinic
      • Columbia, South Carolina, Estados Unidos, 29203
        • Prisma Health-Midlands Clinical Research Unit
      • Greenville, South Carolina, Estados Unidos, 29605
        • Prisma Health Internal Medicine Clinic
    • Tennessee
      • Memphis, Tennessee, Estados Unidos, 38105
        • St Jude Children's Research Hospital
      • Memphis, Tennessee, Estados Unidos, 38103
        • Methodist University Hospital/University of Tennessee Health Science Center, Clinical Research Center
      • Nashville, Tennessee, Estados Unidos, 37208
        • Meharry Medical College Clinical and Transitional Research Center
    • Texas
      • Austin, Texas, Estados Unidos, 78705
        • Central Texas Clinical Research
      • El Paso, Texas, Estados Unidos, 79915
        • Centro San Vincente
      • Houston, Texas, Estados Unidos, 77098
        • The Crofoot Research Center, INC
      • Houston, Texas, Estados Unidos, 77009
        • UT Health Science Center at Houston
    • Washington
      • Seattle, Washington, Estados Unidos, 98104
        • Ofiice of Dr. Peter Shalit, MD
      • Guadalajara C.P., México, 44160
        • Centro de Investigacion Farmaceutica Especializada de Occidente S.C.
      • Barranco, Peru, 15063
        • Asociacion Civil Impacta Salud y Educacion - Sede Barranco
      • Callao, Peru, 7006
        • Instituto de Medicina Tropical "Daniel Alcides Carrion", Facultad de Medicina Humana, UNMSM
      • Iquitos, Peru
        • Asociacion Civil Selva Amazonica
      • Lima, Peru, 15001
        • Via Libre
      • Lima, Peru, 15088
        • Asociacion Civil Impacta Salud y Educacion - Sede San Miguel
    • PR
      • San Juan, PR, Porto Rico, 00717
        • Ararat Research Center
      • San Juan, PR, Porto Rico, 00909
        • Centro Ararat- San Juan
      • Bangkok, Tailândia, 10330
        • King Chulalongkorn Memorial Hospital
      • Bangkok, Tailândia, 10400
        • Ramathibodi Hospital, Mahidol University
      • Bangkok, Tailândia, 10330
        • Institute of HIV Research and Innovation
      • Bangkok, Tailândia, 10330
        • The HIV Netherlands Australia Thailand Research Collaboration (HIV-NAT), Thai Red Cross AIDS research Centre
      • Chiang Mai, Tailândia, 50200
        • Research Institute for Health Sciences, Chiang Mai University
      • Khon Kaen, Tailândia, 40002
        • Srinagarind Hospital, Khon Kaen University
      • Nonthaburi, Tailândia, 11000
        • Bamrasnaradura Infectious Disease Institute
      • Cape Town, África do Sul, 7925
        • Desmond Tutu Health Foundation
      • Johannesburg, África do Sul, 2038
        • Wits Reproductive Health and HIV Institute (Wits RHI)
      • Pretoria, África do Sul, 87
        • The Aurum Institute: Pretoria Clinical Research Centre
      • Soshanguvhe, África do Sul, 0152
        • Setshaba Research Centre
      • Tembisa, África do Sul, 1632
        • The Aurum Institute Tembisa CRC, Clinic 4
      • Vincent, África do Sul, 5217
        • FPD-DTHF Ndevana Commuity Research Site

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

16 anos e mais velhos (Filho, Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Key Inclusion Criteria:

Incidence Phase

  • CGM, TGW, TGM, and GNB who have condomless receptive anal sex with partners assigned male at birth and are at risk for HIV infection.

  • HIV-1 status unknown at screening and no prior HIV-1 testing within the last 3 months.

  • Sexually active with ≥ 1 partner assigned male at birth (condomless receptive anal sex) in the last 12 months and 1 of the following:

    • Condomless receptive anal sex with ≥ 2 partners in the last 12 weeks.
    • History of syphilis, rectal gonorrhea, or rectal chlamydia in the last 24 weeks.
    • Self-reported use of stimulants with sex in the last 12 weeks.

Randomized Phase

  • Negative local rapid fourth generation HIV-1/2 Ab/Ag, central fourth generation HIV-1/2 Ab/Ag, and HIV-1 RNA quantitative nucleic acid amplification testing (NAAT).
  • Estimated glomerular filtration rate (eGFR) ≥ 60 mL/min at screening according to the Cockcroft-Gault formula for creatinine clearance (CLcr).

Key Exclusion Criteria:

Incidence Phase

  • Prior use of HIV PrEP (including F/TDF or F/TAF) or HIV postexposure prophylaxis (PEP) in the past 12 weeks or any prior use of long-acting systemic PrEP (including cabotegravir or islatravir).
  • Prior recipient of an HIV vaccine or HIV broadly neutralizing antibody formulation.

Randomized Phase

  • Acute viral hepatitis A, B or C or evidence of chronic hepatitis B or C infection.
  • Severe hepatic impairment or a history of or current clinical decompensated liver cirrhosis.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Prevenção
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Dobro

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Randomized Blinded Phase: LEN + Placebo-to-match (PTM) F/TDF

Participants will receive the following for up to approximately 52 weeks:

  • Subcutaneous (SC) lenacapavir (LEN) 927 mg every 26 weeks
  • Oral PTM Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) once daily
  • Oral LEN 600 mg on Days 1 and 2

Participants will receive oral LEN if SC injections are not available.

Tablets administered orally without regard to food

Outros nomes:
  • GS-6207

Administered via SC injections

Outros nomes:
  • GS-6207; Yeztugo

Tablets administered orally

Experimental: Randomized Blinded Phase: Placebo LEN + F/TDF

Participants will receive the following for up to approximately 52 weeks:

  • SC LEN placebo every 26 weeks
  • Oral F/TDF 200/300 mg once daily
  • PTM Oral LEN on Days 1 and 2

Participants will receive oral LEN placebo if SC injections are not available.

Tablets administered orally

Outros nomes:
  • Truvada®

Administered via SC injections

Tablets administered orally

Experimental: LEN Open-Label Extension (OLE) Phase

Participants will be offered entry into LEN OLE Phase, following completion of primary analysis, if LEN demonstrates acceptable safety and efficacy in the Randomized Blinded Phase.

Participants randomized to LEN will continue to receive SC LEN 927 mg, every 26 weeks (± 7 days), and have study visits every 13 weeks (± 7 days).

Participants randomized to F/TDF will switch to SC LEN 927 mg on OLE Day 1, Week 26 and every 26 weeks thereafter. Participants will also receive oral LEN 600 mg on OLE Days 1 and 2.

All participants in LEN OLE Phase will complete the phase, once LEN becomes available or the sponsor decides to discontinue the study, whichever happens first.

After completing LEN OLE Phase or study discontinuation, participants will transition to local PrEP, including LEN or other options. If a participant exits early, they will complete an early study drug discontinuation (ESDD), be referred to local PrEP services if needed, and have a 30-day follow-up visit.

Tablets administered orally without regard to food

Outros nomes:
  • GS-6207

Administered via SC injections

Outros nomes:
  • GS-6207; Yeztugo
Experimental: Pharmacokinetic (PK) Tail Phase

Participants who prematurely discontinue study drug during the Randomized Blinded Phase and participants that were randomized to LEN who choose not to continue in the LEN OLE Phase will transition to the PK Tail Phase. Participants will receive oral F/TDF (or Emtricitabine/Tenofovir Alafenamide (F/TAF) for US participants only) once daily for 78 weeks to cover the PK tail and complete visits every 13 weeks (+/- 7 days).

Upon unblinding, participants who were randomized to F/TDF in the Randomized Blinded Phase who decline to participate in the LEN OLE Phase will complete the ESDD visit, transition to local HIV prevention services, and return for a 30-day follow-up visit.

Tablets administered orally

Outros nomes:
  • Truvada®

F/TAF tablets administered orally once daily

Outros nomes:
  • Descovy

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Incidence Phase: Recent Infection Testing Algorithm (RITA) Estimate of the Background Human Immunodeficiency-1 Virus Infection Incidence Rate (bHIV) Per 100 Person Years (PY)
Prazo: Incidence Phase Screening Visit (Day 1)

bHIV per 100 PY in the Incidence Phase was calculated using RITA. The RITA incorporated HIV-1 testing results and recency assay testing results to estimate the bHIV. Recency assay testing was performed for participants in the All Screened Set found to have HIV-1 infection at the Incidence Phase Screening Visit as defined below. Participants were considered to have recent HIV-1 infection if the normalized optical density (ODn) was below 1.5 threshold using the Sedia limiting antigen avidity enzyme immunoassay (LAg-EIA) and the HIV-1 RNA (viral load) was > 75 copies/mL of blood.

HIV-1 infection was defined as participants having at least one of the following central lab results at the Incidence Phase screening visit:

  • Positive HIV-1/2 differentiation Ab, OR
  • Positive HIV-1 ribonucleic acid (RNA) qualitative test, OR
  • HIV-1 RNA quantitative test ≥200 copies/mL.
Incidence Phase Screening Visit (Day 1)
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to Background HIV (bHIV, Participants in All Screened Set)
Prazo: Up to 149 weeks

HIV-1 incidence per 100 PY for LEN was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples. bHIV incidence per 100 PY in All Screened Set was estimated as described in outcome measure#1.

Up to 149 weeks

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Randomized Blinded Phase: HIV-1 Incidence Reported Per 100 PY for LEN Compared to F/TDF
Prazo: Up to 149 weeks

HIV-1 incidence per 100 PY was calculated as the number of participants who acquired HIV-1 divided by the total of a) for participants not diagnosed with HIV-1, sum of all duration of follow-up time in years, while at risk of HIV-1 infection (where a year is 365.25 days) and b) for participants diagnosed with HIV-1, sum of all duration of follow-up time up to confirmed HIV-1 diagnoses. HIV-1 diagnosis was determined by an HIV adjudication committee who reviewed potential HIV-1 infection events in the randomized participants. The committee, in a blinded, consistent, and unbiased manner, determined whether HIV test results confirmed HIV-1 infection and determined the date of diagnosis for each case, defined as the date of the earliest study visit with evidence of HIV infection considering both prospective HIV testing and back-testing of archived samples.

Up to 149 weeks
Randomized Blinded Phase: HIV-1 Incidence Among Participants Adherent to LEN
Prazo: Up to 149 weeks

A participant was defined as adherent to LEN if they have received all per-protocol administrations of LEN within 28 weeks since the previous administration. The incidence of HIV-1 infection per 100 PY calculation is defined in outcome measure #2.

Up to 149 weeks
Randomized Blinded Phase: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
Prazo: First dose date up to 184 weeks

An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a study drug that did not necessarily have a causal relationship with the treatment. TEAEs were defined as 1 or both of the following: Any AEs leading to premature discontinuation of study drug, or any AEs with an onset date on or after the study drug start date and no later than the last exposure date after permanent discontinuation of the study drug.

First dose date up to 184 weeks
Randomized Blinded Phase: Percentage of Participants Experiencing Grade 3 or Higher Laboratory Abnormalities
Prazo: First dose date up to 184 weeks

Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any post-baseline visit, up to and including the last exposure date for participants who permanently discontinued study drug, or the last available date in the database snapshot for participants who were still on treatment at the time of an analysis. The division of acquired immunodeficiency syndrome toxicity grading scale, Version 2.1 was used to assign toxicity grades (0 to 4) to laboratory results for analysis. Grade 0 included all values that do not meet the criteria for an abnormality of at least Grade 1. Grade 1 mild, Grade 2 moderate, Grade 3 severe, and Grade 4 potentially life-threatening. Percentages were rounded off.

First dose date up to 184 weeks

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Gilead Study Director, Gilead Sciences

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Publicações Gerais

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

28 de junho de 2021

Conclusão Primária (Real)

21 de agosto de 2024

Conclusão do estudo (Estimado)

1 de agosto de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

28 de maio de 2021

Enviado pela primeira vez que atendeu aos critérios de CQ

11 de junho de 2021

Primeira postagem (Real)

14 de junho de 2021

Atualizações de registro de estudo

Última Atualização Postada (Real)

6 de outubro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

11 de setembro de 2026

Última verificação

1 de setembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • GS-US-528-9023
  • DOH-27-102021-6681 (Outro identificador: South African National Clinical Trial Registry)
  • 2023 (Concessão/Contrato do NIH dos EUA)
  • 2023-001025-23 (Número EudraCT)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

NÃO

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .